Tissue Engineering: Development of a Scaffold for Cardiac Regeneration

Virginia Leombruni

November 2024

Contents

1 Introduction

Cardiac tissue engineering represents a promising solution for addressing the limited regenerative capacity of the heart following myocardial injury. Heart diseases such as cardiomyopathies result in the progressive loss of cardiac function, and the ability of the heart to self-repair is minimal. Tissue engineering aims to create scaffolds that provide structural support, encourage cell growth, and promote tissue regeneration. Despite significant advancements in the field, there remains a critical need for functional cardiac tissue constructs capable of integrating with the host tissue and restoring normal heart function.

2 Cardiac Tissue Structure and Function

The myocardium, composed predominantly of cardiomyocytes, is responsible for the heart's mechanical contraction and electrical conduction. However, following an injury, such as from myocardial infarction, the heart's natural healing process often results in scar tissue formation, which disrupts the heart's function. While the regenerative potential of cardiac tissue is minimal in adult humans, several studies have explored various strategies to enhance cardiac regeneration. These include stem cell therapies, gene editing, and scaffold-based tissue engineering approaches, with scaffolds providing a favorable microenvironment for cell growth and tissue remodeling.



Figure 1: Cardiac tissue structure.

Recent studies have shown that creating scaffolds that replicate the mechanical and electrical properties of the heart's extracellular matrix (ECM) can significantly enhance tissue integration and functionality. However, achieving optimal mechanical properties and electrical conductivity remains a challenge for scaffold design.



Figure 2: Cardiomyopathy-induced structural damage.

3 Cardiomyopathy

The most common cardiomyopathy is dilated cardiomyopathy which happens when the myocardium weakens and the heart becomes oversized, causing abnormal heart rhythm and infarction. Among them, dilated cardiomyopathy (DCM) is the most common form and is known as one of the most frequent causes of heart failure with reduced ejection fraction [3]. Etiologies of DCM include genetic causes, infection or toxic agents, immune or metabolic diseases and cardiomyopathy associated with pregnancy Approximately 40% of diagnosed DCM cases originate from genetic causes, and their value is probably underestimated because of the heterogeneity of clinical symptoms. Mutations in more than 100 genes have been reported to be involved in the development of DCM. These genes are mainly involved in the force generation or transmission, the mechanosensing, and the structural integrity of the cardiomyocytes, the cardiac contractile cells. For example, the gene encoding the giant protein titin, a component of the sarcomere, is mutated in approximately 20–25

4 Current Challenges in Cardiac Regeneration

Current therapeutic strategies, such as heart transplants and pharmacological treatments, have limitations in addressing the root cause of heart diseases and are often unable to halt disease progression. The use of scaffolds for cardiac tissue engineering aims to provide a long-term solution by regenerating functional tissue that integrates with the heart's native structure. However, several challenges need to be overcome:

- **Scaffold Biocompatibility**: Scaffolds must not induce an inflammatory response or cause any rejection by the body.
- **Mechanical Properties**: The scaffold must have mechanical properties that closely match the native myocardium to withstand the pressure exerted by the heart's contractions.
- **Electrical Conductivity**: Proper electrical conductivity is essential for the synchronization of heart contractions, and scaffolds should promote the propagation of electrical signals.

- **Vascularization**: A crucial challenge is ensuring adequate blood supply to the regenerating tissue, as without sufficient oxygen and nutrient supply, the engineered tissue will not survive.

- **Scaffold Degradation**: Scaffolds should degrade over time as the tissue regenerates, without leaving harmful by-products.

5 Development of a Cardiac Scaffold

This project focuses on creating a biocompatible, biodegradable scaffold for cardiac tissue regeneration. The proposed scaffold consists of a blend of polycaprolactone (PCL), chitosan, polypyrrole, and graphene.

These materials are chosen for their mechanical, electrical, and biological properties, making them suitable for cardiac tissue engineering. PCL, a biodegradable polymer, ensures scaffold structural integrity while gradually degrading over time. Chitosan, derived from chitin, provides biocompatibility and supports cell adhesion, while polypyrrole and graphene enhance the scaffold's electrical conductivity. These materials work together to mimic the natural cardiac tissue environment.



Figure 3: Cardiac tissue scaffold.

5.1 Material Selection

- **Polycaprolactone (PCL)**: PCL is a widely used biodegradable polymer known for its mechanical strength and flexibility. It provides the scaffold with structural integrity while ensuring gradual degradation over time.

- **Chitosan**: Chitosan is a biopolymer derived from chitin, known for its biocompatibility, biodegradability, and ability to support cell adhesion and proliferation. It plays a key role in enhancing scaffold integration with the surrounding tissue.

- **Polypyrrole (PPy)**: Polypyrrole is a conductive polymer that has shown promise in biomedical applications due to its electrical conductivity. Its inclusion helps the scaffold mimic the conductive properties of cardiac tissue, which is essential for maintaining normal heart rhythm.
- **Graphene**: Graphene is incorporated into the scaffold to enhance its electrical conductivity further. It has been shown to improve cell adhesion and proliferation, making it a promising material for promoting myocardial regeneration.

5.2 Fabrication Method

The scaffold is fabricated using the electrospinning technique, which enables the creation of fibers that closely resemble the natural ECM of the myocardium. This process results in nanofibers that offer a high surface area for cell attachment, promoting tissue growth. The electrospinning process allows for the precise control of fiber diameter and orientation, both critical factors for improving scaffold functionality.

5.3 Scaffold Design Considerations

The scaffold design must address the following key factors:

- **Fiber Diameter and Orientation**: The size and arrangement of fibers in the scaffold are crucial for promoting cell growth and alignment, which is particularly important for cardiac tissues with a specific orientation.
- **Porosity**: High porosity is necessary for nutrient and oxygen diffusion and vascularization. The scaffold's porosity should be optimized to allow endothelial cells to migrate and form new blood vessels.
- **Mechanical Strength**: The scaffold must withstand the mechanical forces exerted by the heart during contractions, without compromising cell proliferation and tissue regeneration.
- **Electrical Conductivity**: Ensuring that the scaffold can conduct electrical signals allows it to support synchronized cardiac contractions, improving its functionality in a clinical setting.

6 Experimental Procedure

The scaffold is created using the following experimental procedure:

1. Materials, including PCL, chitosan, polypyrrole, and graphene, are dissolved in appropriate solvents.



Figure 4: Types of scaffolds to model the ECM.



Figure 5: The final scaffold

2. The solution is loaded into the electrospinning device, and parameters such as voltage, flow rate, and distance are optimized.

3. The electrospinning process is carried out, and the scaffold is collected on a rotating drum to ensure uniform fiber alignment.

4. After fabrication, the scaffold is crosslinked to enhance its mechanical strength and stability in biological environments.

5. The scaffold is then seeded with cardiac stem cells or induced pluripotent stem cell-derived cardiomyocytes to promote tissue formation.

7 Challenges and Future Directions

Despite the progress made, challenges remain in optimizing the scaffold for clinical applications:

- **In Vivo Testing**: Although promising results have been obtained in vitro, further studies are required to evaluate the scaffold's performance in animal models. The scaffold's ability to integrate with the host tissue, promote functional tissue regeneration, and restore heart function must be thoroughly tested.

- **Vascularization**: One of the major hurdles is ensuring adequate vascularization of the engineered tissue. Recent studies have explored the incorporation of pro-angiogenic factors into scaffolds to promote blood vessel formation.
- **Scaffold Degradation**: Ensuring that the scaffold degrades at a rate compatible with tissue regeneration is essential. If degradation is too fast, the scaffold will not provide enough support; if too slow, it may impede tissue growth.

Further research is needed to optimize the composition and architecture of the scaffold, as well as to explore the integration of advanced technologies such as 3D bioprinting, which could allow for more precise control over the scaffold's structure and functionality.

8 Conclusion

The development of a conductive, biodegradable scaffold for cardiac tissue regeneration holds great promise for treating heart diseases. By incorporating materials like PCL, chitosan, polypyrrole, and graphene, the scaffold aims to provide the mechanical, biological, and electrical properties necessary for successful tissue regeneration. While significant challenges remain, continued research and optimization of scaffold design will bring us closer to effective therapies for heart regeneration.